Abstract:Importance: MUC16, which encodes cancer antigen 125 (CA-125), is frequently mutated in gastric cancer (GC); however, its association with tumor mutation load (TML) and outcome in patients with GC has not been established, to date.Objective: To investigate whether MUC16 mutations are associated with TML and prognosis in patients with GC.Design, Setting, and Participants: Statistical analysis of genomic data from 437 GC samples obtained from The Cancer Genome Atlas (TCGA) and 256 samples from an Asian cohort. Both cohorts contained data of patients with GC involved in previous genomic studies. Data were obtained from TCGA on September 3, 2017, and from the Asian cohort on March 5, 2013, and analyzed from September 3 to December 1, 2017. The TCGA cohort was used as a discovery set and the Asian cohort as a validation set. Kaplan-Meier survival analysis and multivariate Cox and logistic regression models were applied. Regression models addressed confounding factors; Bayesian variant nonnegative matrix factorization was used to extract mutational signatures. The MutSigCV algorithm was used to identify significantly mutated genes.Main Outcomes and Measures: Primary outcomes were mutation frequency, overall survival, and TML, calculated using Kaplan-Meier survival analysis, odds ratios (ORs), and significance of signaling pathways.Results: MUC16 was mutated in 168 of 437 (38.4%) of the GC samples from the TCGA cohort and in 57 of 256 (22.3%) from the Asian cohort. In both cohorts, GC samples with MUC16 mutations exhibited significantly greater TML than those without MUC16 mutations (median mutation counts: TCGA cohort, 264 with MUC16 mutation vs 115 without; Asian cohort, 134 with MUC16 mutation vs 74 without; Wilcoxon rank sum test, both P < .001). This association was independent of mutations in POLE and BRCA1/2 and mutational signatures in the TCGA cohort (OR, 1.87; 95% CI, 1.49-2.36; P < .001) and the Asian cohort (OR, 1.69; 95% CI, 1.25-2.29; P < .001). MUC16 mutations were significantly associated with better prognosis in both cohorts (median overall survival, 46.9 [95% CI, 26.4-NA (not available)] vs 26.7 [95% CI, 20.2-43.1] months; log-rank test, P = .007 [TCGA cohort] and not calculable [the median overall survival of patients with GC and MUC16 mutations could not be calculated because more than half the patients in the group were alive] vs 36.8 months; P = .04 [Asian cohort]). The association remained statistically significant after controlling for age, sex, TNM stage, mutations in POLE and BRCA1/2, and mutational signatures (hazard ratio, 0.61 [95% CI, 0.42-0.89]; log rank test, P = .01). Immune response and cell cycle regulation circuits were among the top altered signaling pathways in samples with MUC16 mutations (normalized enrichment score, 1.70 [95% CI, 1.57-1.79] and 2.04 [95% CI, 1.90-2.18]; adjusted P < .001). The prognostic significance of MUC16 mutation identified in the TCGA cohort was validated in the Asian cohort.Conclusions and Relevance: These findings indicate that MUC16 mutations may be associated with higher TML, better survival outcomes, and immune response and cell cycle pathways. These findings may be immediately applicable for guiding immunotherapy treatment for patients with GC.

Abstract 1417: Multiple Gastric Cancer and Predisposing Genes

Molecular characteristics of synchronous multiple gastric cancer

Abstract C158: Contribution of multi-organ cancer predisposition genes for gastric cancer risk of different histological subtypes

Abstract B036: Mutational landscape and genetic feature of gastric adenocarcinoma in multiple Chinese ethnicities

Mutational Landscape of Gastric Adenocarcinoma in Chinese: Implications for Prognosis and Therapy.

A Multicenter Study Assessing the Prevalence of Germline Genetic Alterations in Chinese Gastric-Cancer Patients

Abstract 746: Genomic Alteration of Chinese Dmmr/msi-H Gastric Cancer

Pathogenic Germline Mutations in Chinese Patients with Gastric Cancer Identified by Next-Generation Sequencing

A Multi-Institutional Investigation Assessing Prevalence of Germline Genetic Alterations in Chinese Patients with Gastric Carcinoma.

Clonality analysis of synchronous gastroesophageal junction carcinoma and distal gastric cancer by whole-exome sequencing.

A Polymorphism Within The Mismatch Repair Gene Predicts Prognosis And Adjuvant Chemotherapy Benefit In Gastric Cancer Patients.

Germline Mutations And Polymorphic Variants In Mmr, E-Cadherin And Myh Genes Associated With Familial Gastric Cancer In Jiangsu Of China

Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing

Somatic mutations that affect early genetic progression and immune microenvironment in gastric carcinoma

Genomic Alterations in Advanced Gastric Cancer Endoscopic Biopsy Samples Using Targeted Next-Generation Sequencing

Clinical and Genetic Characteristics of Early and Advanced Gastric Cancer

Clinicopathological Features of Tumor Mutation Burden, Epstein-Barr Virus Infection, Microsatellite Instability and PD-L1 Status in Chinese Patients with Gastric Cancer

Abstract 6469: The association of mismatch repair gene alterations with elevated tumor mutational burden in microsatellite stable gastrointestinal cancers

Whole-genome Sequencing Reveals Novel Tandem-Duplication Hotspots and a Prognostic Mutational Signature in Gastric Cancer

Mutational analysis of driver genes with tumor suppressive and oncogenic roles in gastric cancer

Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer